

log, calicheamicin, dolastatin, dolastatin analog, auristatin, tomaymycin derivative, and leptomycin derivative or a prodrug of the cytotoxic agent.

134. The immunoconjugate of claim **133**, wherein the cytotoxic agent is a maytansinoid.

135. The immunoconjugate of claim **134**, wherein the cytotoxic agent is N(2')-deacetyl-N(2')-(3-mercaptopro-1-oxo-propyl)-maytansine (DM1) or N(2')-deacetyl-N(2')-(4-mercaptopro-4-methyl-1-oxopentyl)-maytansine (DM4).

136. The immunoconjugate of claim **128**, wherein the linker is N-succinimidyl 4-(2-pyridylidithio)-2-sulfobutanoate (sulfo-SPDB) and the cytotoxic agent is N(2')-deacetyl-N(2')-(4-mercaptopro-4-methyl-1-oxopentyl)-maytansine (DM4).

137. The immunoconjugate of claim **128**, wherein the antibody or antigen binding fragment thereof comprises a light chain variable domain comprising the amino acid sequence of SEQ ID NO:11.

138. The immunoconjugate of claim **137**, wherein (L) is a linker selected from the group consisting of: a non-cleavable linker, a hydrophilic linker, and a dicarboxylic acid based linker.

139. The immunoconjugate of claim **137**, wherein the linker is selected from the group consisting of: N-succinimidyl 4-(maleimidomethyl) cyclohexanecarboxylate (SMCC); N-sulfosuccinimidyl 4-(maleimidomethyl) cyclohexanecarboxylate (sulfoSMCC); N-succinimidyl-4-(iodo-acetyl)-aminobenzoate (SIAB); and N-succinimidyl-[N-(maleimidopropionamido)-tetraethyleneglycol] ester (NHS-PEG4-maleimide).

140. The immunoconjugate of claim **137**, wherein (L) is a cleavable linker.

141. The immunoconjugate of claim **140**, wherein the linker is selected from the group consisting of: N-succinimidyl 4-(2-pyridylidithio)pentanoate (SPP); N-succinimidyl 4-(2-pyridylidithio)-2-sulfopentanoate (sulfo-SPP); N-succinimidyl 4-(2-pyridylidithio)butanoate (SPDB); and N-succinimidyl 4-(2-pyridylidithio)-2-sulfobutanoate (sulfo-SPDB).

142. The immunoconjugate of claim **137**, wherein the cytotoxic agent is selected from the group consisting of: a maytansinoid, maytansinoid analog, benzodiazepine, taxoid, CC-1065, CC-1065 analog, duocarmycin, duocarmycin analog, calicheamicin, dolastatin, dolastatin analog, auristatin, tomaymycin derivative, and leptomycin derivative or a prodrug of the cytotoxic agent.

143. The immunoconjugate of claim **142**, wherein the cytotoxic agent is a maytansinoid.

144. The immunoconjugate of claim **143**, wherein the cytotoxic agent is N(2')-deacetyl-N(2')-(3-mercaptopro-1-oxo-propyl)-maytansine (DM1) or N(2')-deacetyl-N(2')-(4-mercaptopro-4-methyl-1-oxopentyl)-maytansine (DM4).

145. The immunoconjugate of claim **137**, wherein the linker is N-succinimidyl 4-(2-pyridylidithio)-2-sulfobutanoate (sulfo-SPDB) and the cytotoxic agent is N(2')-deacetyl-N(2')-(4-mercaptopro-4-methyl-1-oxopentyl)-maytansine (DM4).

146. The immunoconjugate of claim **128**, wherein the antibody or antigen binding fragment thereof comprises a light chain comprising the amino acid sequence of SEQ ID NO:13.

147. The immunoconjugate of claim **146**, wherein (L) is a linker selected from the group consisting of: a non-cleavable linker, a hydrophilic linker, and a dicarboxylic acid based linker.

148. The immunoconjugate of claim **146**, wherein the linker is selected from the group consisting of: N-succinimidyl 4-(maleimidomethyl) cyclohexanecarboxylate (SMCC); N-sulfosuccinimidyl 4-(maleimidomethyl) cyclohexanecarboxylate (sulfoSMCC); N-succinimidyl-4-(iodo-acetyl)-aminobenzoate (SIAB); and N-succinimidyl-[N-(maleimidopropionamido)-tetraethyleneglycol] ester (NHS-PEG4-maleimide).

149. The immunoconjugate of claim **146**, wherein (L) is a cleavable linker.

150. The immunoconjugate of claim **149**, wherein the linker is selected from the group consisting of: N-succinimidyl 4-(2-pyridylidithio)pentanoate (SPP); N-succinimidyl 4-(2-pyridylidithio)-2-sulfopentanoate (sulfo-SPP); N-succinimidyl 4-(2-pyridylidithio)butanoate (SPDB); and N-succinimidyl 4-(2-pyridylidithio)-2-sulfobutanoate (sulfo-SPDB).

151. The immunoconjugate of claim **146**, wherein the cytotoxic agent is selected from the group consisting of: a maytansinoid, maytansinoid analog, benzodiazepine, taxoid, CC-1065, CC-1065 analog, duocarmycin, duocarmycin analog, calicheamicin, dolastatin, dolastatin analog, auristatin, tomaymycin derivative, and leptomycin derivative or a prodrug of the cytotoxic agent.

152. The immunoconjugate of claim **151**, wherein the cytotoxic agent is a maytansinoid.

153. The immunoconjugate of claim **152**, wherein the cytotoxic agent is N(2')-deacetyl-N(2')-(3-mercaptopro-1-oxo-propyl)-maytansine (DM1) or N(2')-deacetyl-N(2')-(4-mercaptopro-4-methyl-1-oxopentyl)-maytansine (DM4).

154. The immunoconjugate of claim **146**, wherein the linker is N-succinimidyl 4-(2-pyridylidithio)-2-sulfobutanoate (sulfo-SPDB) and the cytotoxic agent is N(2')-deacetyl-N(2')-(4-mercaptopro-4-methyl-1-oxopentyl)-maytansine (DM4).

155. The immunoconjugate of claim **128**, wherein the antibody or antigen binding fragment thereof is a full length antibody.

156. The immunoconjugate of claim **128**, wherein the antibody or antigen binding fragment thereof is an antigen binding fragment, wherein the antigen binding fragment comprises a Fab, a Fab', a F(ab')², a single chain Fv (scFv), a disulfide linked Fv, an IgG-CH2, a F(ab')³, a tetrabody, a triabody, a diabody, a (scFv)², or a scFv-Fc.

157. The immunoconjugate of claim **128**, wherein the antibody binds to human FOLR1 with a Kd of 1.0 nM or better.

158. The immunoconjugate of claim **128**, wherein the antibody binds to human FOLR1 with a Kd of about 0.06 nM to about 1.0 nM.

159. The immunoconjugate of claim **128**, further comprising 2-6 (C).

160. The immunoconjugate of claim **128**, wherein the antibody or antigen binding fragment further comprises a second and third (C).

161. A pharmaceutical composition comprising the immunoconjugate of claim **129** and a pharmaceutically acceptable carrier, wherein the immunoconjugates have an average of 3 to 4 (C) per (A).